Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,403 across all filing types
Latest filing 2018-12-03 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BLOCK LISTING INTERIM REVIEW
Regulatory Filings
2018-12-03 English
TOTAL VOTING RIGHTS
Regulatory Filings
2018-12-03 English
Block listing Interim Review
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by AstraZeneca PLC via the Regulatory News Service (RNS). It details the issuance of shares under various employee share option plans over a six-month period. This type of filing, which reports on changes to share capital resulting from employee schemes, falls under the category of share issues or capital changes.
2018-12-03 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document explicitly starts with an 'RNS Number' and mentions that the information is provided by 'RNS, the news service of the London Stock Exchange,' which is approved by the FCA. The content details the total number of voting rights and issued share capital as of a specific date (30 November 2018), which is a regulatory disclosure required under the Transparency Directive. This type of mandatory, periodic disclosure that doesn't fit into specific financial reports (like 10-K or IR) or specific corporate actions (like DIV or SHA) is best classified as a general Regulatory Filing (RNS). Although it relates to voting rights, it is a notification about the capital structure denominator, not the results of a vote (DVA) or a proxy solicitation (PSI).
2018-12-03 English
GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED
Regulatory Filings
2018-12-03 English
Grünenthal Agreement for Nexium, Vimovo Completed
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 1354J' and contains information about a completed agreement regarding drug rights divestment, including financial details ($700m, $115m) and regulatory references (Listing Rule 10.4.1R). The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit mention of RNS strongly indicate a general regulatory announcement disseminated via the London Stock Exchange's news service. Since the content is a specific corporate action (divestment completion) that doesn't fit perfectly into the other specific categories (like 10-K, ER, or DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2018-12-03 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.